Skip to content
lifestyle.claritypointe.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Cognition Therapeutics, Inc.
Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB
September 30, 2026
Cognition Therapeutics to Present at H.C. Wainwright Conference
September 8, 2026
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update
August 6, 2026
Cognition Therapeutics Participating in Upcoming Investor Conferences
June 1, 2026
Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
May 25, 2026
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
May 24, 2026
Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update
May 21, 2026
Cognition Therapeutics to Present at Needham Virtual Healthcare Conference
April 7, 2026
Cognition Therapeutics CEO Issues Letter to Shareholders
March 31, 2026
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update
March 26, 2026
1
2
Next Page
→